Up­dat­ed: GSK takes vic­to­ry lap with block­buster sales for RSV vac­cine

GSK is look­ing to ride the mo­men­tum from its RSV vac­cine sales in­to 2024 and be­yond. Mean­while, it has cut three in­fec­tious dis­ease can­di­dates from its pipeline, two of which were un­der an al­liance with Vir Biotech­nol­o­gy.

Its RSV vac­cine Arexvy has of­fi­cial­ly reached block­buster sta­tus, rak­ing in £1.2 bil­lion in 2023. In con­trast, Pfiz­er’s Abrys­vo, which was ap­proved in the same month, on­ly drew $890 mil­lion. Arexvy hit the block­buster mile­stone in four months, which is “the fastest pace” in its his­to­ry, CEO Em­ma Walm­s­ley said dur­ing a call with me­dia on Wednes­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER